RxDoctor Payments Data

Erik Miller

Internal Medicine · Warsaw, MONPI 1235131723

Payments from drug & device makers

$900in general payments, 2019–2025

Across 54 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$178
  • Merck$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75
  • Pfizer$70
  • AstraZeneca$70
  • Sunovion Pharmaceuticals Inc.$56
  • plus $342 from 15 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$182,616
FarxigaDapagliflozin Propanediol198$169,486
TrulicityDulaglutide77$92,631
JardianceEmpagliflozin97$84,203
EliquisApixaban81$59,814
XareltoRivaroxaban64$57,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$55,690
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$40,719
Stiolto RespimatTiotropium Br/Olodaterol Hcl67$40,602
MounjaroTirzepatide33$35,208
Spiriva RespimatTiotropium Bromide41$27,848
VraylarCariprazine Hcl16$24,102
Tresiba Flextouch U-100Insulin Degludec11$20,498
ByettaExenatide20$18,899
TradjentaLinagliptin27$18,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Byetta, Bevespi Aerosphere$70$239,161293 claims
Novo NordiskOzempic$35$182,616179 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Tradjenta, Combivent Respimat$16$176,804243 claims
Lilly USA, LLCTrulicity, Mounjaro$16$127,838110 claims
PfizerEliquis$70$59,81481 claims
AbbVieVraylar$178$24,10216 claims
MerckBelsomra$109$18,54645 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$14$11,64913 claims
NovartisEntresto$53$8,31812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Warsaw

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →